Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qianhai Health HoldingsHKSE:00911 +14.29%39 Return-on-Tangible-Equity is 0.60% as of Dec. 2025, which is 445% above its 10-year median of 0.11. GuruFocus rates HKSE:00911 with a GF Score™ of 39/100 and a GF Value™ of HK$0.22 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 895 Drug Manufacturers companies, Qianhai Health Holdings ranks worse than 68.27% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Qianhai Health Holdings's annualized net income for the quarter that ended in Dec. 2025 was HK$2.3 Mil. Qianhai Health Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$390.6 Mil. Therefore, Qianhai Health Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 0.60%.
The historical rank and industry rank for Qianhai Health Holdings's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:00911'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -93.27 Med: 0.11 Max: 6.04
Current: 1.53
During the past 13 years, Qianhai Health Holdings's highest Return-on-Tangible-Equity was 6.04%. The lowest was -93.27%. And the median was 0.11%.
HKSE:00911's Return-on-Tangible-Equity is ranked worse than 68.27% of 895
companies
in the Drug Manufacturers industry
Industry Median: 7.85
vs HKSE:00911: 1.53
Qianhai Health Holdings (HKSE:00911) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Qianhai Health Holdings Return-on-Tangible-Equity Related Terms
Qianhai Health Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Qianhai Health Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qianhai Health Holdings Return-on-Tangible-Equity Chart
HKSE:00911 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Qianhai Health Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qianhai Health Holdings Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Qianhai Health Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Qianhai Health Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.60% mean?
Qianhai Health Holdings (HKSE:00911) has a Return-on-Tangible-Equity of 0.60% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qianhai Health Holdings and its competitors. This is 445% above median its historical median of 0.11. According to the industry distribution chart, Qianhai Health Holdings ranks #611 out of 895 companies in the Drug Manufacturers industry, placing it in the top 68.3%.
Is Qianhai Health Holdings' Return-on-Tangible-Equity too high?
Qianhai Health Holdings' current Return-on-Tangible-Equity of 0.60% is 445% above median its 10-year median of 0.11. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.85. Qianhai Health Holdings' value of 0.60% is 92.4% below this industry median. Based on the distribution chart, Qianhai Health Holdings ranks #611 out of 895 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Qianhai Health Holdings has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qianhai Health Holdings' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Qianhai Health Holdings ranks #611 out of 895 companies for Return-on-Tangible-Equity. This places Qianhai Health Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.85. Qianhai Health Holdings' value of 0.60% is 92.4% below this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 7.85, Qianhai Health Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.85, based on 895 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qianhai Health Holdings's current Return-on-Tangible-Equity of 0.60% is 92.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qianhai Health Holdings and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qianhai Health Holdings's current Return-on-Tangible-Equity is 0.60%, which is 445% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qianhai Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Qianhai Health Holdings (HKSE:00911) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$0.60 — trading 172.7% above its estimated fair value. The current Return-on-Tangible-Equity is 0.60%, which is 445% above median its 10-year median of 0.11 and 92.4% below the Drug Manufacturers industry median of 7.85. Qianhai Health Holdings' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Qianhai Health Holdings (HKSE:00911), the current Return-on-Tangible-Equity is 0.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qianhai Health Holdings (HKSE:00911) Overvalued in 2026?
Based on GuruFocus' analysis, Qianhai Health Holdings stock appears to be overvalued.
The current stock price of HK$0.60 is trading 172.7% above its estimated GF Value™ of HK$0.22.
GuruFocus considers Qianhai Health Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:00911:
Return-on-Tangible-Equity: 0.60% (445% above median its 10-year median of 0.11)
GF Value™: HK$0.22 vs. price of HK$0.60 (172.7% above fair value)
Industry Position: 92.4% below the Drug Manufacturers median (#611 of 895)
No single metric tells the full story. See the HKSE:00911 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qianhai Health Holdings Ltd principally engaged in the sale of health products and electronic component products. It includes Chinese herbal medicines, skin-care and other healthcare products, and the sale of information technology components. The operating segments of the group are Healthcare products and Electronic component products. Healthcare products include the sale of healthcare products, including Chinese herbal medicines, skincare, and other healthcare products. Electronic component products include the sale of information technology components products including central processing units and semiconductors. The group's revenue is all derived from Hong Kong.
39GF Score
Get the complete analysis for HKSE:00911
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00911 has been successfully added to your 
